Traders should monitor for potential short-term downward pressure due to share dilution, though the capital strengthens the balance sheet for upcoming commercial and clinical milestones. The use of proceeds supports long-term value creation if barzolvolimab gains approval and achieves market uptake.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $31.06entry
- T+1 · 8mo ago +1.00%α +0.52% · $31.37
- T+5 · 7mo ago +3.80%α +0.18% · $32.24
- T+20 · 7mo ago +5.86%α −4.02% · $32.88
- T+60 · 5mo ago +19.80%α +5.64% · $37.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 million in gross proceeds. The company may sell an additional 1,551,750 shares via an underwriter option, and plans to use the funds for commercial readiness of barzolvolimab, clinical development, and general corporate purposes.
Key Financial Metrics
Key Facts
- Celldex is offering 10,345,000 shares at $29.00 per share.
- Gross proceeds expected: ~$300 million (excluding underwriter option).
- Underwriters have a 30-day option to purchase up to 1,551,750 additional shares.
- Proceeds will fund commercial launch of barzolvolimab (if approved), clinical development, platform expansion, and general corporate needs.
- Offering expected to close April 6, 2026, subject to customary conditions.
Financial Impact
$300 million gross proceeds, with potential for $44.5 million more if underwriters fully exercise their option (total ~$344.5M). Dilution estimated at ~10.5% of current market cap ($2.1B).
Risk Factors
- Dilution from new share issuance may pressure stock price near closing.
- Forward-looking statements carry uncertainty around future commercial and clinical outcomes.
- Market conditions could affect final execution if underwriters exercise their option.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267105 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers